Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PARP”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT06078670
What this trial is testing

PARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
Fujian Cancer Hospital 96
Early research (Phase 1)Ended earlyNCT03182673
What this trial is testing

The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors

Who this might be right for
Solid Tumor
Jiangsu HengRui Medicine Co., Ltd. 31
Testing effectiveness (Phase 2)Looking for participantsNCT07504588
What this trial is testing

Sacituzumab Govitecan With Bevacizumab Compared to Usual Chemotherapy (Carboplatin, Pegylated Liposomal Doxorubicin and Bevacizumab) for Treating Recurrent Platinum-Sensitive Ovarian Cancer After PARP Inhibitor Maintenance Therapy

Who this might be right for
Recurrent Platinum-Sensitive Fallopian Tube Endometrioid AdenocarcinomaRecurrent Platinum-Sensitive Fallopian Tube High Grade Serous AdenocarcinomaRecurrent Platinum-Sensitive Ovarian High Grade Endometrioid Adenocarcinoma+3 more
National Cancer Institute (NCI)
Not applicableUnknownNCT05255861
What this trial is testing

An Exploratory Study of HRD Score in Chinese Ovarian Cancer Patients Benefiting From PARP Inhibitor Targeted Therapy

Who this might be right for
Ovarian Cancer
Xin Wu 300
Testing effectiveness (Phase 2)Active Not RecruitingNCT04034927
What this trial is testing

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

Who this might be right for
Fallopian Tube Endometrioid TumorFallopian Tube High Grade Serous AdenocarcinomaMalignant Ovarian Endometrioid Tumor+11 more
National Cancer Institute (NCI) 61
Testing effectiveness (Phase 2)Looking for participantsNCT06502691
What this trial is testing

[18F]FTT Positron Emission Tomography for the Measurement of PARP Tumor Expression in Patients With Metastatic Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast Carcinoma
University of Washington 22
Early research (Phase 1)Study completedNCT00553189
What this trial is testing

Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas

Who this might be right for
Solid TumorsLymphomas
National Cancer Institute (NCI) 31
Testing effectiveness (Phase 2)Study completedNCT01173497
What this trial is testing

A Study Evaluating INIPARIB in Combination With Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Who this might be right for
Estrogen Receptor Negative (ER-Negative) Breast CancerProgesterone Receptor Negative (PR-Negative) Breast CancerHuman Epidermal Growth Factor Receptor 2 Negative (HER2-Negative) Breast Cancer+1 more
Sanofi 44
Testing effectiveness (Phase 2)Ended earlyNCT06065059
What this trial is testing

Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors

Who this might be right for
Breast CancerOvarian CancerPancreas Cancer+5 more
Tango Therapeutics, Inc. 7
Early research (Phase 1)WithdrawnNCT01419548
What this trial is testing

ABT-888, Carboplatin, and Paclitaxel for Cancer With Liver or Kidney Problems

Who this might be right for
Neoplasms
National Cancer Institute (NCI)
Not applicableLooking for participantsNCT06603506
What this trial is testing

Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study

Who this might be right for
Endometrial Cancer
Centre Francois Baclesse 16
Testing effectiveness (Phase 2)Looking for participantsNCT06525298
What this trial is testing

EIS-12656 as Single Agent and in Combination in Patients With Specified Solid Tumors

Who this might be right for
Advanced Solid TumorHomologous Recombination DeficiencyHRR Deficiency
Eisbach Bio GmbH 144
Testing effectiveness (Phase 2)Study completedNCT05938374
What this trial is testing

Preoperative Moderately Fractionated IMRT for Locally Extremity or Trunk Sarcoma (SPARE-03)

Who this might be right for
Soft Tissue Sarcoma
Cancer Institute and Hospital, Chinese Academy of Medical Sciences 52
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07723651
What this trial is testing

[18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)

Who this might be right for
Metastatic Prostate CancerProstate Cancer
Washington University School of Medicine 75
Testing effectiveness (Phase 2)Ended earlyNCT05297864
What this trial is testing

PARP Inhibition for Gliomas (PI-4G or π4g)

Who this might be right for
Recurrent GlioblastomaRecurrent AstrocytomaRecurrent Oligodendroglioma+1 more
University of Oklahoma 15
Testing effectiveness (Phase 2)Ended earlyNCT00271167
What this trial is testing

A Trial of INO-1001 in Patients Undergoing Heart Surgery That Involves Heart-lung Bypass

Who this might be right for
Heart DiseasesPostoperative Complications
Inotek Pharmaceuticals Corporation 162
Early research (Phase 1)WithdrawnNCT02627430
What this trial is testing

Talazoparib and HSP90 Inhibitor AT13387 in Treating Patients With Metastatic Advanced Solid Tumor or Recurrent Ovarian, Fallopian Tube, Primary Peritoneal, or Triple Negative Breast Cancer

Who this might be right for
Adult Solid NeoplasmEstrogen Receptor NegativeFallopian Tube Serous Neoplasm+10 more
National Cancer Institute (NCI)
Testing effectiveness (Phase 2)Ended earlyNCT04483544
What this trial is testing

Pembrolizumab and Olaparib in Cervical Cancer Patients

Who this might be right for
Cervical CancerCervical Carcinoma
Baptist Health South Florida 8
Large-scale testing (Phase 3)Study completedNCT04676334
What this trial is testing

CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib

Who this might be right for
Metastatic Castration-Resistant Prostate CancerOvarian CancerEpithelial Ovarian Cancer+3 more
pharmaand GmbH 34
Early research (Phase 1)Study completedNCT03551171
What this trial is testing

The Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of ZL-2306 (Niraparib) in Patients With Ovarian Cancer

Who this might be right for
Ovarian Cancer
Zai Lab (Shanghai) Co., Ltd. 42
Next Page
87